click on circles to display study description...

NeoTRIPaPDLA, 0 NCT02620280

atezolizumab plus carboplatin plus nab-paclitaxel (n=88) vs. carboplatin plus nab-paclitaxel (n=86)

randomized controlled trial

Studied treatment

atezolizumab plus carboplatine plus nab-paclitaxel
day 1 every 3 weeks plus carboplatine AUC 2 plus nab-paclitaxel 125mg/m2 weekly for 2 weeks every 3 weeks for 8 cycle

Control treatment

carboplatine plus nab-paclitaxel
carboplatine AUC 2 plus nab-paclitaxel 125mg/m2 weekly for 2 weeks every 3 weeks for 8 cycle

all patient received the treatment followed by surgery, and 4 cycles f AC/EC/FEC

Patients

es-BC - TNBC - NA - all population

Method

open label

Remark

Addition of atezolizumab to neoadjuvant chemo (carboplatin plus nab-paclitaxel) did not improve pCR rate (secondary endpoint), 5 year EFS (primary endpoint) is not reported yet